Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 3/20 | 0.34 |
| ▸ | CDK8 | P49336 | 3/20 | 0.34 |
| ▸ | HASPIN | Q8TF76 | 3/20 | 0.34 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29726297 | 1.00 | KDM1A (0.34) | KDM1ACHRNB2CHRNA4CCNCCDK8 | |
| SCHEMBL23001516 | 0.88 | CHRNB2 (0.42) | CHRNB2CHRNA4CCNCCDK8HASPIN | |
| SCHEMBL22980505 | 0.75 | USP19 (0.31) | NAMPT | |
| SCHEMBL29993055 | 0.74 | PDE3B (0.35) | NAMPT | |
| SCHEMBL25713322 | 0.74 | CDC7 (0.40) | CCNCCDK8HASPINCDK19 | |
| SCHEMBL20511884 | 0.70 | MAPKAPK2 (0.33) | — | |
| Trifluoroacetic Acid SCHEMBL14995239 | 0.70 | L3MBTL1 (0.37) | HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL30365543 | 0.70 | L3MBTL1 (0.37) | HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL30343298 | 0.70 | CHRNB2 (0.56) | KDM1ACHRNB2CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL6434973 | 0.68 | NPSR1 (0.39) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289753-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-09-15 | — | — | US | disclosed |
| EP-4010335-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021028362-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289753-A1 | SHP2 INHIBITORS | PTPN1, PTPN2, PTPN7 | KDM1A 872/4885CHRNB2 4792/4885CHRNA4 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.